RecruitingNCT06458088

Advanced Glycation Products and Vascular Complications in Type 1 Diabetes

Advanced Glycation Products and the Incidence of Vascular Complications in Type 1 Diabetes: DIABAGE Study After More Than 5 Years

Sponsor

CHU de Reims

Enrollment

196 participants

Start Date

Jan 25, 2023

Study Type

OBSERVATIONAL

Conditions

Type1diabetes

Summary

DIABAGE (Diabetes Advanced Glycation End products) study was conducted between 2015 and 2017. It included 196 type 1 diabetic patients with more than 10 years of diabetes. It revealed a significant association between the occurrence of vascular complications and tissular Advanced Glycation End products (AGEs) as well as with some circulating AGEs. This protocol is a continuation of that initial research.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is a follow-up to an earlier research project (DIABAGE) looking at a group of type 1 diabetes patients. It is examining whether a type of cellular damage marker called advanced glycation products (compounds formed when sugar attaches to proteins) is linked to blood vessel complications in people with type 1 diabetes over time. **You may be eligible if...** - You were already enrolled in the initial DIABAGE study - You receive follow-up care at Reims hospital **You may NOT be eligible if...** - You did not participate in the original DIABAGE study - You refuse to participate in this follow-up Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.